Inhibition of the signal transducer and activator of transcription 3 (STAT3) signaling pathway is a novel therapeutic strategy to treat human cancers with constitutively active STAT3. During the screening of natural products to find STAT3 inhibitors, we identified 2′-hydroxycinnamaldehyde (HCA) as a STAT3 inhibitor, which was isolated from the stem bark of Cinnamomum cassia. In this study, we found that HCA inhibited constitutive and inducible STAT3 activation in STAT3-activated DU145 prostate cancer cells. HCA selectively inhibited the STAT3 activity by direct binding to STAT3, which was confirmed by biochemical methods, including a pull-down assay with biotin-conjugated HCA, a drug affinity responsive target stability (DARTS) experiment and a cellular thermal shift assay (CETSA). HCA inhibited STAT3 phosphorylation at the tyrosine 705 residue, dimer formation, and nuclear translocation in DU145 cells, which led to a downregulation of STAT3 target genes. The downregulation of cell cycle progression and antiapoptosis-related gene expression by HCA induced the accumulation of cells in the G0/G1 phase of the cell cycle and then induced apoptosis. We also found that reactive oxygen species (ROS) were involved in the HCAinduced inhibition of STAT3 activation and cell proliferation because the suppressed p-STAT3 level was rescued by glutathione or N-acetyl-L-cysteine treatment, which are general ROS inhibitors. These results suggest that HCA could be a potent anticancer agent targeting STAT3-activated tumor cells.
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| INTRODUC TI ON
Signal transduction and activator of transcription factor 3 (STAT3) is a transcription factor that regulates various cellular process such as proliferation, survival and angiogenesis in cancer cells.
1 STAT3
is persistently activated in many cancers and multiple oncogenic pathways converge on STAT3. 2 STAT3 is constitutively activated in various types of cancer cells, including pancreatic, lung, colorectal, ovarian, prostate, cervical, breast, brain and renal cancer, as well as melanoma, glioma, lymphoma and leukemia. 3, 4 In response to cytokines and growth factors, STAT3 is phosphorylated at the tyrosine 705 residue and forms homodimers, followed by translocation into the nucleus. 1 The activated STAT3 dimers bind to and activate the promoters of STAT3 target genes, which are involved in the regulation of the cell cycle and apoptosis. 5 As a potential therapeutic target for cancer therapy, natural and synthetic inhibitors targeting the STAT3 pathway have been developed. 1, 6 These inhibitors are categorized according to their site of action, including the SH2 domain or dimerization, upstream tyrosine kinases (eg, JAK1/2, SRC), STAT3 decoy oligonucleotides, STAT3-DNA domain binding and negative regulators of STAT3. 1 Numerous studies have confirmed their potential for clinical use; however, only a few compounds, such as OPB-51602, AZD1480, dasatinib, STA-21 and pyrimethamine, have progressed to early-phase clinical trials. [7] [8] [9] Thus, novel strategies of STAT3-targeted therapies are being explored to overcome unpredictable pharmacokinetics, limited efficacy and selectivity, and severe toxicity.
Cancer cells exhibit increased reactive oxygen species (ROS) levels compared to normal cells, which can be exploited for the selective killing of cancer cells. 10 In cancer cells, the levels of antioxidant proteins are usually upregulated to remove the ROS as a mechanism to escape apoptosis. 11 Therefore, ROS-targeted anticancer agents effectively kill cancer cells and overcome drug resistance by enhancing ROS generation and/or inhibiting the antioxidant defense. 10, 12 The tumor suppressive function of ROS is mediated by apoptosis, autophagy and necroptosis. 12 To reveal the mechanism of action of HCA, several molecular targets of HCA have been identified and the underlying mechanisms have been investigated in various cancer cells. [20] [21] [22] In colon cancer cells, HCA induces apoptosis by inhibiting the L3-like activity of the proteasome, resulting in the increase of endoplasmic reticulum stress and mitochondrial perturbation. 20 In breast cancer cells, HCA attenuates cell invasion through stimulating the oxidation of thiols in the extracellular LRP1, LRP1 ligand binding, and extracellular pepsin clearance. 21 Moreover, HCA directly binds to the Pim-1 ATP-binding pocket and inhibits the Pim-1 kinase activity in leukemia and skin cancer cells. 22 Although the proteasome subunits, LRP1 and Pim-1 were identified as direct targets of HCA, different modes of action associated with the binding target of HCA have not been completely understood.
In the present study, we identified STAT3 as a direct target of HCA using various biochemical methods, such as a pull-down assay, a drug affinity responsive target stability (DARTS) experiment and a cellular thermal shift assay (CETSA), and determined its antiproliferative activity in DU145 prostate cancer cells with constitutively active STAT3. HCA suppressed cell proliferation through inhibiting the tyrosine phosphorylation of STAT3 at tyrosine 705, dimer formation and nuclear translocation. The expressions of STAT3-regulated genes associated with cell cycle progression and anti-apoptosis were downregulated by treatment with HCA. In addition to STAT3 inactivation, HCA increased the levels of intercellular ROS and ERK1/2 activation. HCA-induced ROS production and STAT3 inactivation were inhibited by treatment with antioxidants.
In conclusion, HCA selectively suppressed cell proliferation and induced cell apoptosis in STAT3-activated DU145 cells through STAT3 inactivation and ROS generation.
| MATERIAL SANDME THODS

| Cellculture
All cell lines used in this study were originally obtained from the ATCC (Manassas, VA, USA). DU145 and LNCaP (human prostate cancer), as well as HCT-116 (human colon cancer) cells were maintained in RPMI 1640 medium (Gibco, Gaithersburg, MD, USA). MCF-10A (human mammary epithelial) cells were maintained in DMEM-F12 (Gibco).
All culture media were supplemented with 10% heat-inactivated FBS (Gibco), 100 U/mL penicillin and .1 mg/mL streptomycin (SigmaAldrich, St. Louis, MO, USA). Cell cultures were maintained in a 37°C
incubator under a humidified atmosphere with 5% CO 2 .
| Cellproliferationassay
The cells were seeded in 96-well plates in medium containing 10%
FBS. After 24 hours, the wells were replenished with fresh complete medium containing either a test compound or .1% DMSO. After incubation for 24-72 hours, the cell proliferation reagent WST-1 (Dojindo Laboratories, Kumamoto, Japan) was added to each well.
The amount of WST-1 formazan that was produced was measured at 450 nm using the Multiskan GO system (Thermo Fisher Scientific, Rockford, IL, USA).
| Dual-luciferasereporterassay
The reporter assay was performed using the 21pSTAT3-TA-Luc reporter vector that carries the STAT3-binding element for firefly 
| FACSanalyses
Cells were trypsinized at specific times after compound treatment and were collected by centrifugation at 250 g for 5 minutes at room temperature. The supernatant was discarded, and the precipitated and analyzed with LSM Version 3.2 software (Carl Zeiss). 
| Reactiveoxygenspeciesmeasurement
| Synthesisofbiotin-2′-hydroxycinnamaldehyde
| Pull-downassay
| Drugaffinityresponsivetargetstability
The DARTS experiment was conducted as previously described with some modifications. 23 
| Cellularthermalshiftassay
The CETSA was conducted using cell and tissue lysates as previously described. 24 For CETSA with cell lysates, DU145 cells were 
| Knockdownoftargetgenes
Small interfering RNA (siRNA) against each gene were preincubated for 20 minutes in serum-free Opti-MEM (Gibco) containing the Lipofectamine RNAiMAX Reagent (Invitrogen, Carlsbad, CA, USA). Scrambled and STAT3 siRNA were purchased from Bioneer (Daejeon, Republic of Korea). RPMI 1640 medium containing 10% FBS was added 6 hours after incubation. After 48 hours, the transfected cells were collected and used for the experiments described.
| Westernblotting
Cell lysates were prepared in RIPA lysis buffer containing a protease inhibitor cocktail (Roche Diagnostics). Proteins (20-50 μg)
were resolved by 8%-15% SDS-PAGE and transferred to PVDF membranes (EMD Millipore, Billerica, MA, USA 
| Invivoxenograftassay
Animal experiments were performed in accordance with a pro- 
| Statisticalanalysis
All experiments were performed at least twice, and multiple samples represent biological (not technological) replicates. All animal experiments were performed using randomly assigned mice without investigator blinding. No statistical methods were used to predetermine the sample size, and no data were excluded. Statistical analyses were performed using Excel. Statistical significance was tested using 2-tailed t tests. Values of P < .05, P < .01 and P < .001 are denoted by *, ** and ***, respectively.
| RE SULTS
| 2′-Hydroxycinnamaldehydesuppressescell proliferationviaregulationofsignaltransducerand activatoroftranscription3activity
To identify STAT3 inhibitors, we screened 650 natural products using the STAT3 reporter assay by luciferase in HCT-116 colon cancer cells. 25 After the dual luciferase assay for the STAT3 activity, we identified HCA as a potent STAT3 inhibitor ( Figure 1A ). 
| 2′-Hydroxycinnamaldehydebindsto signaltransducerandactivatoroftranscription 3andinhibitssignaltransducerandactivatorof transcription3activity
To elucidate the underlying mechanism of STAT3 inactivation by HCA, we analyzed the dimerization and translocation into the Our data suggest that HCA binds directly to STAT3 and inhibits dimer formation as well as the nuclear translocation of STAT3.
| 2′-Hydroxycinnamaldehydespecificallybinds tosignaltransducerandactivatoroftranscription3in DU145cells
To further confirm the direct binding and its specificity with STAT3, we performed label-free target validation assays, including DARTS After treatment, the cell cycle distribution was analyzed using a FACSCalibur flow cytometer (n = 2). The ratios of cells in each phase were analyzed using the WinMDI 2.9 analyzer which are inhibited by ROS scavenger treatment. 27 We evaluated the effect of HCA on ROS generation using FACSCalibur flow cytometer, and the intracellular ROS level was measured by DCF-DA.
After time-dependent treatment with HCA, the intracellular ROS level of DU145 cells was greatly increased at 30 minutes and then maintained for up to 6 hours after treatment with HCA ( Figure 5A ).
ROS activates multiple MAP kinase signaling pathways such as the ERK1/2, JNK, p38 MAPK and BMK 1 pathways. 13 In addition, the generation of ROS induces apoptosis by inactivating the STAT3 signaling pathway. 16 Notably, ERK1/2 activation was observed at 
| 2′-Hydroxycinnamaldehydesuppresses cellproliferationandtumorgrowthviasignal transducerandactivatoroftranscription3 inactivationandreactiveoxygenspeciesgeneration
To further confirm HCA-induced STAT3 inactivation, we applied Figure 6E ). It has been reported that ROS induces apoptosis by inactivating the STAT3 signaling pathway. 16 Interestingly, HCAinduced ROS generation was synergistically increased in STAT3
siRNA-treated cells compared to scrambled siRNA-treated cells ( Figure 6F ). Moreover, HCA still induced ERK1/2 activation in STAT3 knockdown cells ( Figure 6G ). Therefore, our data suggest that HCA inhibited cell proliferation by inactivating STAT3 and inducing ROS production, respectively, and STAT3 is also involved in HCA-induced ROS generation.
We treated DU145 cells with the ERK1/2 inhibitor U0126 and 
| D ISCUSS I ON
Because of the advantages of herbal medicine-based drugs with low toxicity, several natural STAT3 inhibitors have been developed as potential anticancer therapeutics, including curcumin, butein, capsaicin, celastrol, diosgenin, thymoquinone, resveratrol, piperlongumine and vitamin E. 5 Piperlongumine (PL), a natural product isolated from the Piper longum Linn., induces apoptosis by inhibiting STAT3 activity and increasing the intracellular level of ROS. 31, 32 PL inhibits the phosphorylation and nuclear translocation of STAT3 by inhibiting its direct binding to the phosphotyrosyl peptide ligand. 32 Curcumin, an active component of turmeric (Curcuma longa), has antitumor activity by targeting the SH2 domain of STAT3. 33, 34 Although curcumin has been reported to be safe at doses as high as 8 g/d in humans, its low bioavailability in serum leads to the development of curcumin with modifications. 35 In addition, cryptotanshinone from Salvia miltiorrhiza Bunge (Danshen) is a potent STAT3 inhibitor that targets the SH2 domain of STAT3. 25 Our data show that HCA also inhibits the STAT3 activity by directly binding to STAT3 ( Figures 3C and 4) .
Furthermore, preclinical evaluations of HCA show that HCA is a safe Current targeted therapeutics targeting a single key factor lead to the acquisition of drug resistance and relapse due to highly redundant and bypassable signaling pathways. 36 Multitarget agents have attracted attention as potential therapeutic solutions to diseases of complex disorders and drug resistance. 37, 38 Natural products are a historically rich source of biologically active compounds for cancer treatment. 39 Therefore, the potential of natural products is discussed as a starting point for multitarget drug discovery. As multitarget drugs, compounds have multiple but concrete molecular targets while maintaining their beneficial broad target profile. 37 For multitarget drug development, the concrete molecular targets . The band intensity of each protein was quantified using the MultiGauge program. *P < 0.01; **P < 0.05; ***P < 0.001; n.s., not significant. Data represent mean ± SD should be elucidated to minimize side effects and adverse compensatory mechanisms. For example, natural products, such as curcumin, EGCG, resveratrol, salicylate and quercetin, are considered to be valuable leads for multitarget drugs. 37 In this study, we suggest STAT3 as one of the multiple molecular targets of HCA as well as the proteasome subunits, LRP1 and Pim-1 kinase. [20] [21] [22] Further elaborate elucidation of molecular targets and systemic understanding of their interactions will help us to design more effective and safe multitarget drugs for cancer treatment.
Natural products, such as curcumin, sugiol, EGCG, PL and resveratrol, produce ROS and induce apoptotic cell death, resulting in the activation of caspase and PARP degradation. 27, 31, 40, 41 Curcumin 
U0126
or PL-induced apoptosis is mediated by ROS and the activation of ERK1/2, which is blocked by antioxidant treatment. 31, 40 Sugiol isolated from the roots of salvia has antitumor activity through the inhibition of transketolase, which leads to ROS production and MEG2
activation. 41 As a derivative of HCA, BCA produce ROS, and BCAinduced apoptosis is abolished by the pretreatment of cells with antioxidants. 27 Similarly, ROS generation and ERK1/2 activation were observed 1 hour after treatment with HCA, which was blocked by pretreatment with NAC or GSH ( Figure 5 ).
Reactive oxygen species activate MAP kinase signaling pathways and are involved in the regulation of a variety of biological processes. 13 In addition to ROS-mediated MAPK activation, ROS generation leads to the inactivation of STAT3 signaling. 16, 41 Sugiol induces STAT3 dephosphorylation at Tyr705, which is abrogated by treatment with antioxidants or the ERK inhibitor U0126. 41 HCA-induced STAT3 dephosphorylation was rescued by pretreatment with antioxidants, NAC or GSH ( Figure 5C HCA, which has a relatively low toxicity and is a multitargeting agent, may be a more promising candidate for antitumor drug development.
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